z-logo
open-access-imgOpen Access
Irritable bowel syndrome and the Rome III criteria: for better or for worse?
Author(s) -
KokAnn Gwee
Publication year - 2007
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0b013e328013c0fa
Subject(s) - irritable bowel syndrome , medicine , bloating , functional constipation , referral , constipation , rifaximin , family medicine , diarrhea , microbiology and biotechnology , biology , antibiotics
The paper by Sperber et al. in this issue is an early evaluation of the Rome III criteria against the Rome II criteria for irritable bowel syndrome that throws up several important observations. A three to four-fold increase was observed in irritable bowel syndrome prevalence with the Rome III criteria. Individuals with the Rome II criteria had more doctor visits, perception of stress and a negative global feeling. There could be a shift of individuals between irritable bowel syndrome and other functional bowel disorder diagnostic groups such as functional constipation and functional bloating. In this review, it is suggested that rigid application of the symptom frequency and duration requirements of the older Rome criteria could have introduced a selection bias for patients with greater psychological disturbance, and that this could have impacted negatively on our perception and management of irritable bowel syndrome. The findings of Sperber et al. suggest that the new Rome III criteria may enable us to pay more attention to the average irritable bowel syndrome patient we see in our clinics as opposed to the chronically severe patient. It is proposed that improved management of our average patient may translate into better outcomes in terms of reduction in specialist referral, unnecessary surgery and potentially harmful alternative treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here